AARD logo

AARD Aardvark Therapeutics, Inc. Common Stock

NASDAQ Global Select · Biotechnology · Healthcare

$0.92
-0.08 (-7.74%)

Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It func…

Market Cap: $20.20Maardvarktherapeutics.com

Price

No data yet.

Social Signal Score

28
5d
—
30d
—
60d
38
2 mentions
—
90d
18
7 mentions
—
news: 7

Analyst Ratings

10 analysts
Buyconsensus
Strong Buy 0Buy 5Hold 4Sell 1Strong Sell 0
Avg price target$2.4+160.1%
Low $1.5Median $2High $4
Current Consensus

Revenue

$0.00
$0.00
Sep 2023Sep 2026

Analyst Estimates

FY2025
$-2.93
$-3.04–$-2.81
9 analysts
FY2026
$-3.30
$-3.78–$-2.69
7 analysts
FY2027
$-2.40
$-3.44–$-1.37
9 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Tien-Li Lee
Sector
Healthcare
Industry
Biotechnology
Employees
28
Beta
3.81
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
-4.69
aardvarktherapeutics.com